Response to the Revision of the EU General Pharmaceuticals Legislation

HAI Statement on The Oslo Medicines Initiative at the WHO Virtual Consultation with Non-State Actors, 31 March 2021

Response to EU’s HERA Initiative Consultation

Transparency, Accountability and Access to Medicines: European Projects 2021

How the Netherlands and other EU Governments Respond to the Challenge of Sustainable Access to Medicines

Statement to EB148 on WHO reform: involvement of non-State actors in WHO’s governing bodies

Letter to Dr Tedros: Leadership and Advocacy for C-TAP

Statement to EB148 on expanding access to effective treatments for cancer and rare and orphan diseases, including medicines, vaccines, medical devices

Statement to EB148 on the COVID-19 response

Statement to EB148 on global strategy and plan of action on public health, innovation and intellectual property

Access to Internationally Controlled Essential Medicines in sub-Saharan Africa


Joint HTA Assessment in Europe: Progress in 2020

Cross-country Cooperation Schemes: A fair-weather solution to the issue of access to medicines in Europe?

FACT SHEET: Impact and Knowledge of COVID-19 and related measures in rural Kenyan households

Making Medicines Authorisation Procedures Work for Patients

Clinical Trial Transparency in the Netherlands: Mapping Unreported Drug Trials

European Commission Intellectual Property Action Plan

Partners for Change

SRHC: Availability, Affordability and Stock-outs – Uganda 2019

Driving Change in Access to Medicines – Annual Report 2019

COVID-19 Technology Access Pool

SRHC: Availability, Affordability and Stockouts – Zambia 2019

Letter to Dr Tedros: The Challenge of Access to Insulin Amidst COVID-19

Results from the HSA Partnership’s Learning Agenda

The fight against COVID-19: let’s make public investments count for people

SRHC: Availability, Affordability and Stockouts- Kenya 2019

EU Priorities 2020-2024: Medicines policy that works for people

Patient-centred Advocacy: HAI’s Work in Europe 2020

Statement to EB146 on non-State actors on official relations with WHO

Statement to EB146 on Global Strategy and Plan of Action on Public Health, Innovation and Intellectual Property